KindredBio Board of Directors
Mr. Veszprémi previously served as the Vice President and Global Head of Marketing at Novartis Animal Health, one of the largest veterinary companies in the world. Prior to that position, he served as the Country Head of Ciba-Geigy Animal Health Spain. He is currently CEO of Medichem, a leading Active Pharmaceutical Product manufacturer, and has almost 30 years of experience in the pharmaceutical industry, including 15 in the animal health sector. Mr. Veszprémi holds a physiology degree from University of British Columbia and has studied management at Harvard Business School and Stanford.
Raymond Townsend, PharmD
Dr. Townsend is a pioneer in the pharmacoeconomics field. He was formerly the Worldwide Director and Vice President, Outcomes, Epidemiology and Policy Research at Glaxo. He also served as Senior Vice President, Pharmacoeconomic & Epidemiology Outcomes Research, at Elan Pharmaceuticals, Inc. Dr. Townsend earned a B.A. in Economics at California State University and his Doctor of Pharmacy degree from the University of California, San Francisco.
Herbert D. Montgomery
Mr. Montgomery has extensive experience in finance, including having served as CFO of several public companies, and having taken three companies public. Most recently, he was Vice Chairman of the Board and Executive Officer of Lightpost Holdings, LLC. Prior to that, Mr. Montgomery was Executive Vice President, Chief Financial Officer, and Treasurer of Standard Media International; Senior Vice President, Chief Financial Officer and Treasurer of Cotelligent, Inc.; and Senior Vice President, Chief Financial Officer and Treasurer of Guy F. Atkinson. He holds a Master of Science degree in Management and a Bachelor of Science degree in Finance from California State University, Northridge. Mr. Montgomery was also previously Chairman of the Board of Institute for OneWorld Health.
Richard Chin, MD
Founder and Chief Executive Officer
Richard Chin is a Harvard-trained physician and a former Rhodes Scholar with a track record of almost a dozen drug approvals and over 50 INDs. Drugs Richard developed, including Lucentis®, Xolair®, Tysabri®, and Rituxan® for immune diseases, have current aggregate sales of well over $10 billion per year.
Previously, Richard was Head of Clinical Research for the Biotherapeutics Unit at Genentech where he oversaw all of Genentech’s drug development programs except oncology products; Senior VP of Global Development at Elan; CEO of Oxigene, a NASDAQ-listed biotechnology company; and CEO of OneWorld Health, a Gates Foundation-funded nonprofit developing drugs for impoverished patients in developing countries. Richard was named by BusinessWeek in 2006 as one of 99 youngest public company CEOs in the United States. He has authored several major textbooks on clinical development and teaches drug development at UCSF.